Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages 638-644

  Cybulski, Cezary ^a   Kluźniak, Wojciech ^a   Huzarski, Tomasz ^a   Wokołorczyk, Dominika ^a   Kashyap, Aniruddh ^a   Jakubowska, Anna ^a   Szwiec, Marek ^b   Byrski, Tomasz ^a   Debniak, Tadeusz ^a   Górski, Bohdan ^a   Sopik, Victoria ^c   Akbari, Mohammad R ^c   Sun, Ping ^c   Gronwald, Jacek ^a   Narod, Steven A ^c   Lubiński, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Regional Oncology Center   (Poland)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; PALB2 GENE; POLISH CITIZEN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; TUMOR INVASION; BREAST NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MUTATION; PATHOLOGY; RISK FACTOR; VERY ELDERLY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; RECEPTOR, ERBB-2; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84930278374     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70142-7     Document Type: Article

References (21)

1. Erkko H, Dowty JG, Nikkila J, et al. Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 2008, 14:4667-4671.
2. Papi L, Putignano AL, Congregati C, et al. A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer 2010, 9:181-185.
3. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res 2011, 71:2222-2229.
4. Southey MC, Teo ZL, Dowty JG, et al. A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 2010, 12:109.
5. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167.
6. Janatova M, Kleibl Z, Stribrna J, et al. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiol Biomarkers Prev 2013, 22:2323-2332.
7. Noskowicz M, Bogdanova N, Bermisheva M, et al. Prevalence of PALB2 mutation c.509_510delGA in unselected breast cancer patients from Central and Eastern Europe. Fam Cancer 2014, 13:137-142.
8. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014, 371:497-506.
9. Erkko H, Xia B, Nikkila J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007, 446:316-319.
10. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 2007, 9:83.
11. Dansonka-Mieszkowska A, Kluska A, Moes J, et al. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet 2010, 11:20.
12. Laduca H, Stuenkel AJ, Dolinsky JS, et al. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 2014, 16:830-837.
13. Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2015, 121:25-33.
14. Heikkinen T, Karkkainen H, Aaltonen K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res 2009, 15:214-222.
15. Tischkowitz M, Xia B PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res 2010, 70:7353-7359.
16. Teo ZL, Provenzano E, Dite GS, et al. Tumour morphology predicts PALB2 germline mutation status. Br J Cancer 2013, 109:154-163.
17. Cybulski C, Lubinski J, Wokolorczyk D, et al. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clin Genet 2014, published online Nov 13. http://dx.doi.org/10.1111/cge.12524.
18. Gronwald J, Raczyński A, Tarhoni M, et al. Population screening for cancer family syndromes in the West Pomeranian region of Poland. Hered Cancer Clin Pract 2006, 4:56.
19. Gorski B, Byrski T, Huzarski T, et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 2000, 66:1963-1968.
20. Azzato EM, Greenberg D, Shah M, et al. Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?. Br J Cancer 2009, 100:1806-1811.
21. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.